Michael Gelband’s Sionna Therapeutics SION Stock Holding History

Michael Gelband’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,190	Closed	-$288K	–	2192
2026 Q1	$288K	Buy	+7,190	New	+$274K	﹤0.01%	1317

Other funds holding SION

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Michael Gelband's SION Position: Q2 2026 in Review

Michael Gelband sold out of Sionna Therapeutics (SION) in Q2 2026, closing a stake of 7,190 shares — an estimated $288K sold.

Michael Gelband first reported a position in SION in Q1 2026 and held it in 1 quarter. The position peaked at $288K in Q1 2026. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

Michael Gelband reported no remaining Sionna Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 7,190 Sionna Therapeutics shares in Q2 2026, an estimated $288K.
Michael Gelband first reported a position in Sionna Therapeutics in Q1 2026 and held it in 1 quarter.
Michael Gelband's Sionna Therapeutics position peaked at $288K in Q1 2026.
146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.